AYTU BIOPHARMA, INC(AYTU)— Stock Profile, AI Score & Financials

Healthcare · Nasdaq · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated 2026-03-31.

AYTU BIOPHARMA, INC (AYTU) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores AYTU at 23.4/100 on a 32-signal composite quality model, placing it at rank #2,727 of 2,962 stocks — the bottom half of the AI-ranked universe. AYTU scores in the top quartile across institutional flow (99.5). Areas of concern include revenue growth (6.8) and balance sheet strength (8.1), which score below median versus the broader universe. Based on the latest XBRL financial filings (Q1 2026), AYTU BIOPHARMA, INC reports quarterly revenue of $12.4M, net income of $-5.6M, an operating margin of -32.8%. Top institutional holders of AYTU by reported 13-F value include Stonepine Capital Management, Nantahala Capital Management, AWM Investment Company, based on the most recent SEC filings. AYTU trades on the Nasdaq exchange and files with the SEC under CIK 1385818. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate AYTU daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for AYTU BIOPHARMA, INC directly from SEC EDGAR.